Abstract
The survival of patients with metastatic non-small cell lung cancer (NSCLC) has been increasing with immunotherapy, yet efficient biomarkers are still needed to optimize patient care. In this study, we explored the benefits of multimodal approaches to predict immunotherapy outcome using multiple machine learning algorithms and integration strategies. We leveraged a novel multimodal cohort of 317 metastatic NSCLC patients treated with first-line immunotherapy, collecting at baseline positron emission tomography images, digitized pathological slides, bulk transcriptomic profiles, and clinical information. Most integration strategies investigated yielded multimodal models surpassing both the best unimodal models and established univariate biomarkers, such as PD-L1 expression. Additionally, several multimodal combinations demonstrated improved patient risk stratification compared to models built with routine clinical features only. Our study thus provided new evidence of the superiority of multimodal over unimodal approaches, advocating for the collection of large multimodal NSCLC cohorts to develop and validate robust and powerful immunotherapy biomarkers.
Competing Interest Statement
Nicolas Girard has a consulting or advisory role for the following companies: Abbvie, AMGEN, AstraZeneca, BeiGene, Bristol-Myers Squibb, Daiichi Sankyo/Astra Zeneca, Gilead Sciences, Ipsen, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, Takeda. The other authors declare no potential conflict of interest.
Funding Statement
This work was part of the TIPIT project (Towards an Integrative approach for Precision ImmunoTherapy) funded by Fondation ARC call SIGN′IT 2020—Signatures in Immunotherapy. The present study was also supported by the French government under management of Agence Nationale de la Recherche as part of the Investissements d′avenir program, reference ANR-19-P3IA-0001 (PRAIRIE 3IA Institute).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of Institut Curie gave ethical approval for this work (DATA200053).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflict of interest disclosure statement: Nicolas Girard has a consulting or advisory role for the following companies: Abbvie, AMGEN, AstraZeneca, BeiGene, Bristol-Myers Squibb, Daiichi Sankyo/Astra Zeneca, Gilead Sciences, Ipsen, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, Takeda.
The other authors declare no potential conflict of interest.
- Competing Interest Statement corrected - Table 1 corrected (switching figures for men and women) - Subsection "Genomic data" of "Methods" section updated
Data Availability
The raw data generated in this study, including PET/CT scans, digitized pathological slides, and RNA-seq profiles, are not publicly available due to patient privacy requirements. Derived transcriptomic, radiomic, and pathomic features as well as clinical information are available upon reasonable request from the corresponding author.
The transcriptomic features as well as the clinical features associated with the 195 TCGA patients with stage III-IV NSCLC are publicly available (https://github.com/ncaptier/multipit/tree/main/data).
